© 2019 by Aparito | Privacy Policy

Newton funded epilepsy study starts enrolling patients

Scroll Down

Dr. Elin Haf Davies

Thu Sep 13 2018 12:30:00 GMT+0000 (Coordinated Universal Time)

The Red Cross War Memorial Children’s Hospital, Cape Town South Africa in partnership with Aparito, a Welsh based digital health company recruited their first patient in June following the successful deployment of Atom 5 – a software platform to enable next generation remote patient monitoring.

The study is designed to recruit 40 paediatric patients from 4 years of age to test the feasibility of remote patient monitoring in South Africa by using wearable devices, smart phone apps and a clinical portal. Over the summer months the clinical team successfully recruited 11 patients and will continue recruiting until early 2019. Patients will then be monitored using the technology for a period of up to 9 months. The wearable:app combination has been designed to support medication adherence, real-time seizure recordings (including video uploads where safe and possible to do so), sleep and activity and quality of life and patient reported outcomes reporting. As part of the study patients also consent to have genetics testing at the University of Cape Town in an effort understand more about the specific genetics of epilepsy in that population and to enable precision medicine to become more accessible to all. Principle Investigator Dr Karen Fieggen reported “We’re very happy to have our first patients using the Atom 5 system. Given the specific demographics and location of the patients that we’re supporting it has required some effort to enable this, but as technology continues to evolve and become ever more available, affordable and accessible we see the potential of this approach to be significant for improving care for our patients”. Dr Elin Haf Davies, CEO of Aparito added, “We applaud the clinical team who has worked extremely hard to enable the deployment of our technology in South Africa and thank them for sharing our vision that such technology can serve to bring benefits to all patients in the future, regardless of their geographic location”. The team plan to present their first set of results at the Southern African Society for Human Genetics in August 2019.